Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study
Authors
Blandine Guffroy
Maryam Idlhaj
Gabriel Brisou (ORCID: https://orcid.org/0000-0003-0771-683X)
Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study
Blandine Guffroy, Maryam Idlhaj, Gabriel Brisou, Luc‐Matthieu Fornecker et al.
Journal
Haematologica
Topics
Lymphoma Diagnosis and Treatment
article
Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study
Blandine Guffroy, Maryam Idlhaj, Gabriel Brisou, Luc‐Matthieu Fornecker, Adrien Chauchet, David Beauvais, Stéphanie Guidez, Emmanuel Bachy, Fabien Claves, Vincent Camus, Pierre Sesques, Violaine Safar, Adrien Caillet, Emmanuelle Ferrant, Carl J. Rudebeck, François‐Xavier Gros, Herv Ghesquieres, Camille Golfier, Ludovic Fouillet, Hamza Manjra
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Lyon College (US), Centre Hospitalier Universitaire de Bordeaux (FR), Université de Poitiers (FR), Centre Hospitalier Universitaire de Besançon (FR), Institut de Cancérologie Strasbourg (FR), Hospices Civils de Lyon (FR), Centre Hospitalier Universitaire de Poitiers (FR), Neurocentre Magendie (FR), Institut Paoli-Calmettes (FR), Hôpital Claude Huriez (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Hôpital Albert Michallon (FR), Centre Henri Becquerel (FR)